Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05034874Phase 2Terminated

Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

Role: lead

NCT04715230Phase 2Terminated

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Role: lead

NCT05027451Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of IXT-m200

Role: lead

NCT03336866Phase 1Completed

Study of Antibody for Methamphetamine Outpatient Therapy

Role: lead

NCT01603147Phase 1Completed

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Role: lead

All 5 trials loaded